RU2019121279A - SUB-UNIT VACCINE AGAINST MYCOPLASMA SPP - Google Patents

SUB-UNIT VACCINE AGAINST MYCOPLASMA SPP Download PDF

Info

Publication number
RU2019121279A
RU2019121279A RU2019121279A RU2019121279A RU2019121279A RU 2019121279 A RU2019121279 A RU 2019121279A RU 2019121279 A RU2019121279 A RU 2019121279A RU 2019121279 A RU2019121279 A RU 2019121279A RU 2019121279 A RU2019121279 A RU 2019121279A
Authority
RU
Russia
Prior art keywords
adjuvant
pharmaceutically acceptable
composition
eutd
freund
Prior art date
Application number
RU2019121279A
Other languages
Russian (ru)
Other versions
RU2759427C2 (en
RU2019121279A3 (en
Inventor
Цзюнн-Хорнг ЛИНЬ
Цзюйх-Пернг ВАН
Мин-Вэй СИЭХ
Цзен-Вэн ЧЭНЬ
Чиэнь-Юй ФАН
Суэх-Тао ЛЮ
Пин-Чэн ЯН
Original Assignee
Эгрикалчурал Текнолоджи Рисерч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эгрикалчурал Текнолоджи Рисерч Инститьют filed Critical Эгрикалчурал Текнолоджи Рисерч Инститьют
Priority to RU2019121279A priority Critical patent/RU2759427C2/en
Publication of RU2019121279A publication Critical patent/RU2019121279A/en
Publication of RU2019121279A3 publication Critical patent/RU2019121279A3/ru
Application granted granted Critical
Publication of RU2759427C2 publication Critical patent/RU2759427C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/30—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Claims (13)

1. Композиция для профилактики инфекции Mycoplasma spp., содержащая:1. Composition for the prevention of infection with Mycoplasma spp., Containing: эффективное количество белка EutD в качестве активного ингредиента указанной композиции; иan effective amount of EutD protein as an active ingredient in said composition; and фармацевтически приемлемый адъювант;a pharmaceutically acceptable adjuvant; где указанный EutD имеет последовательность SEQ ID NO: 10.wherein said EutD has the sequence SEQ ID NO: 10. 2. Композиция по п.1, в которой концентрация указанного активного ингредиента составляет от 50 до 3500 мкг/мл из расчета на общий объем указанной композиции.2. A composition according to claim 1, wherein the concentration of said active ingredient is from 50 to 3500 μg / ml, based on the total volume of said composition. 3. Композиция по п.1, в которой указанный фармацевтически приемлемый адъювант представляет собой полный адъювант Фрейнда, неполный адъювант Фрейнда, гель оксида алюминия, поверхностно-активное вещество, полианионный адъювант, пептид, масляную эмульсию или их комбинацию.3. A composition according to claim 1, wherein said pharmaceutically acceptable adjuvant is Freund's complete adjuvant, Freund's incomplete adjuvant, an alumina gel, a surfactant, a polyanionic adjuvant, a peptide, an oil emulsion, or a combination thereof. 4. Композиция для профилактики инфекции Mycoplasma spp., содержащая:4. Composition for the prevention of infection with Mycoplasma spp., Containing: эффективное количество белка EutD в качестве активного ингредиента указанной композиции;an effective amount of EutD protein as an active ingredient in said composition; фармацевтически приемлемый адъювант; иa pharmaceutically acceptable adjuvant; and фармацевтически приемлемую добавку;a pharmaceutically acceptable additive; где указанный EutD имеет последовательность SEQ ID NO: 10.wherein said EutD has the sequence SEQ ID NO: 10. 5. Композиция по п.4, в которой указанный фармацевтически приемлемый адъювант представляет собой полный адъювант Фрейнда, неполный адъювант Фрейнда, гель оксида алюминия, поверхностно-активное вещество, полианионный адъювант, пептид, масляную эмульсию или их комбинацию.5. A composition according to claim 4, wherein said pharmaceutically acceptable adjuvant is Freund's complete adjuvant, Freund's incomplete adjuvant, an alumina gel, a surfactant, a polyanionic adjuvant, a peptide, an oil emulsion, or a combination thereof. 6. Композиция по п.4, в которой указанная фармацевтически приемлемая добавка представляет собой растворитель, стабилизатор, разбавитель, консервант, антибактериальный агент, противогрибковый агент, изотонический агент, замедляющий абсорбцию агент или их комбинацию.6. A composition according to claim 4, wherein said pharmaceutically acceptable additive is a solvent, stabilizer, diluent, preservative, antibacterial agent, antifungal agent, isotonic agent, absorption delaying agent, or a combination thereof.
RU2019121279A 2019-07-08 2019-07-08 Subunit vaccine against mycoplasma spp RU2759427C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2019121279A RU2759427C2 (en) 2019-07-08 2019-07-08 Subunit vaccine against mycoplasma spp

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2019121279A RU2759427C2 (en) 2019-07-08 2019-07-08 Subunit vaccine against mycoplasma spp

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2018132357A Division RU2695679C1 (en) 2018-09-11 2018-09-11 Subunit vaccine against mycoplasma spp

Publications (3)

Publication Number Publication Date
RU2019121279A true RU2019121279A (en) 2021-01-11
RU2019121279A3 RU2019121279A3 (en) 2021-08-05
RU2759427C2 RU2759427C2 (en) 2021-11-12

Family

ID=74185183

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019121279A RU2759427C2 (en) 2019-07-08 2019-07-08 Subunit vaccine against mycoplasma spp

Country Status (1)

Country Link
RU (1) RU2759427C2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE134705T1 (en) * 1988-06-29 1996-03-15 Ml Technology Ventures RECOMBINANT HYOPNEUMONIAE ANTIGEN AND USE THEREOF
ES2729579T3 (en) * 2001-07-02 2019-11-04 Zoetis Services Llc Single dose vaccine with Mycoplasma hyopneumoniae

Also Published As

Publication number Publication date
RU2759427C2 (en) 2021-11-12
RU2019121279A3 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
RU2015137851A (en) SUB-UNIT VACCINE AGAINST MYCOPLASMA SPP.
JP5517454B2 (en) Methods and pharmaceutical compositions for the treatment and prevention of hepatitis C infection
JP2018527306A (en) Stabilized antimicrobial peptide
WO2001089559A3 (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
WO2021262826A3 (en) 1'-cyano nucleoside analogs and uses thereof
WO2007130493A3 (en) Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
ES2548677T3 (en) Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof
BR0214188A (en) Monoclonal antibodies to hepatitis viruses and / or fragments thereof with binding activity and use thereof
WO2004103315A3 (en) Treatment of ophthalmic infections using antimicrobial peptides
RU2012157399A (en) PEPTIDES AS ACTIVE AGENTS FOR STABILIZING BIOLOGICAL BARRIERS
RU2019121279A (en) SUB-UNIT VACCINE AGAINST MYCOPLASMA SPP
ATE290548T1 (en) EXPRESSION BLOCKING OF VIRULENT FACTORS IN S. AUREUS
CN103505729B (en) A kind of stable rabies virus human antibody combination preparation
JP2006512078A5 (en)
Bolzonello et al. Peptide analogs of a Trichoderma peptaibol effectively control downy mildew in the vineyard
WO2022011110A3 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
US20230072433A1 (en) Compositions and methods for treatment of fungal infections
RU2015125699A (en) ANTIGENS AND ANTIGEN COMBINATIONS PSEUDOMONAS
WO2015171924A3 (en) Inhibitors of fusion between viral and cell membranes as well as compositions and methods of using them
RU2009113831A (en) IPAD PROTEIN SHIGELLA AND ITS APPLICATION AS A VACCINE AGAINST SHIGELLA INFECTIONS
HRP20140819T1 (en) Compositions and methods for preventing or treating aids
RU2017130457A (en) VACCINE FOR LAWSONIA SUBCLINICAL INFECTION IN PIGS
Bikshapathy et al. Effect of introducing p-fluorophenylalanine and multiple tryptophan residues in a 13-residue antibacterial peptide
ZHAO et al. Effects of microbial biocontrol agents on several important fungal diseases of strawberry
US20180169209A1 (en) FSBM Recombinant Protein